Security
Iambic Therapeutics, Inc. Common Stock · IAM
IAMNASDAQCommon stockCurrentCIK 1997038Updated Nov 21, 2026
IAM price & chart
Loading TradingView…
NASDAQ:IAM on TradingView ↗About the company
We are a technology and clinical-stage life sciences company pursuing a fundamental shift in the biopharmaceutical industry. Our mission is to make better technology for better medicines. We do this by integrating leading proprietary, large-scale artificial intelligence (AI) with automated, scalable chemistry and biology experimentation. We call this approach molecular superintelligence.
In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G - filed by Qatar Investment Authority regarding Iambic Therapeutics, Inc.
4 filing
4 filing
Show 5 more recent filings
Offerings
Registration 333-299057
- Gross proceeds
- 150000000.0
- Net proceeds
- 139500000.0
- Deal price
- 16.0
- Shares
- 9375000
- Offering price
- $16.00
- Ticker
- IAM
Underwriters: J.P. Morgan Securities LLC, Jefferies LLC, BofA Securities, Inc., Citigroup Global Markets Inc.
Filing attachments
iam-ex4_3.htm · 10-Q · 2026-11-19
Exhibit 4.3 THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION…
Read attachment ↗iam-ex99_1.htm · 8-K · 2026-11-16
Exhibit 99.1 Iambic Provides Business Updates and Third Quarter 2026 Financial Results • Launched Enchant® v3, a 41-billion-parameter transformer model for drug discovery and development, to drive decisions across our internal and partnership activities • Signed AI discovery collaborations with Bayer and AbbVie; eight total partnerships signed since 2024 • Achieved a program milestone in Takeda collaboration, triggering a $1.0 million payment; AI-driven drug discovery collaboration was annou…
Read attachment ↗iam-ex4_1.htm · S-1 · 2026-09-21
Exhibit 4.1 IAMBIC THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of April 1, 2026, by and among Iambic Therapeutics, Inc., a Delaware corporation (the “Company”), the Key Holders (as defined below), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” and any Additional Purchaser (as defined in the Purchase Agreement) tha…
Read attachment ↗iam-ex4_2.htm · S-1 · 2026-09-21
Exhibit 4.2 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR PURSUANT TO RULE 144 OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE CORPORATION AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED. WARRANT TO PURCHASE STOCK Issuer: Entos, Inc., a Delaware corporation (the “Company”) Number of Shares: 1…
Read attachment ↗